Isoniazida Labesfal

Isoniazid, the active ingredient in Isoniazida Labesfal, is an antitubercular presented as an injectable for intramuscular use. It treats active and latent tuberculosis in adults and children.

GNH USA supplies Isoniazida Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoniazid is an antitubercular drug used within the Mycobacterium tuberculosis treatment pathway.

- Active tuberculosis: forms part of combination therapy to eradicate Mycobacterium tuberculosis. - Latent tuberculosis infection: used alone or with rifampicin to prevent progression to active disease. - Pediatric tuberculosis: administered under medical supervision to treat TB in children.

Isoniazid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, especially in the extremities. - Hepatotoxicity: elevated liver enzymes, mild jaundice. - Nausea or vomiting. - Rash or mild skin eruption. - Fever or flu‑like symptoms. - Loss of appetite.

Serious or Rare Side Effects: - Severe hepatitis: jaundice, dark urine, abdominal pain. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Drug‑induced lupus erythematosus. - Seizures, especially in overdose. - Anaphylactic reaction. - Agranulocytosis or severe neutropenia.

Before initiating therapy, clinicians should assess liver function and consider patient‑specific risk factors.

- Liver monitoring: obtain baseline hepatic enzymes and repeat periodically. - Alcohol use: avoid or limit alcohol consumption to reduce hepatotoxic risk. - Pyridoxine supplementation: give vitamin B6 to prevent peripheral neuropathy, especially in high‑risk patients. - Pregnancy: category B; use only if benefits outweigh potential risks. - Renal impairment: adjust monitoring as needed for patients with severe kidney disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isoniazid interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Rifampicin: increased hepatotoxicity when used together. - Pyrazinamide: additive liver toxicity in combination regimens. - Alcohol: synergistic risk of liver injury. - Carbamazepine, Phenytoin, Phenobarbital: enzyme induction reduces isoniazid levels. - HIV protease inhibitors: may increase isoniazid concentrations.

Moderate Interactions (Monitor Closely): - Acetylation status: slow acetylators have higher plasma levels. - Vitamin B6 (pyridoxine): high doses may reduce isoniazid efficacy. - Warfarin: monitor INR as isoniazid can affect anticoagulation. - Antacids containing aluminum or magnesium: may decrease absorption if oral formulation used. - Antiretroviral drugs (e.g., efavirenz): monitor for neuropsychiatric effects.